EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Frequency and Functional Characterization of RUNX1 Germline Variants in Myeloid Neoplasms

Nikolaj Juul Nitschke iD, Marwa Almosailleakh iD, Yiyuan Niu iD, Jakob Werner Hansen iD, Klas Raaschou-Jensen iD, Jakob Schmidt Jespersen iD, Marianne Tang Severinsen iD, Anne Stidsholt Roug iD, Morten Frödin iD, Joachim Lütken Weischenfeldt, Mette Klarskov Andersen, Kirsten Grønbæk iD

Human Mutation · 02.06.2023 · 2023 · 1-11

DOI: 10.1155/2023/4738660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, erschienen am 02.06.2023. Verfasst von Nikolaj Juul Nitschke und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Germ-Line Mutation, Myeloproliferative Disorders, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, Rigshospitalet’s Research Foundation, Danish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current estimates suggest that up to 10% of patients with myeloid neoplasms (MN) harbor variants associated with a germline predisposition. A pathogenic variant in the runt-related transcription factor 1 gene (RUNX1) is a frequent cause of germline predisposition to MN. RUNX1 variants detected in tumor tissue at a VAF close to 50% are potentially germline and causative of RUNX1 familial platelet disorder with associated myeloid malignancies. Previous studies have found germline RUNX1 variants in 3% of patients with acute myeloid leukemia; however, the frequency of germline RUNX1 variants in less advanced myeloid neoplasms has not been examined. We screened 590 patients suspected of MN, excluding myeloproliferative neoplasms, for germline variants in RUNX1. We found RUNX1 variants in 83 patients (14%) by targeted sequencing of tumor tissue. In 40 patients (6.8%), the VAF of RUNX1 was above 30%. In 32 of the 40 patients, skin biopsies were available and used for Sanger sequencing to assess the germline status. Two of the tested variants (6.3%) were confirmed as germline, and both variants were curated as variants of unknown significance. To further explore the pathogenicity of these variants, we implemented a novel CRISPR-Select functional genetic assay. The assay demonstrated a profound effect on proliferation in K562 cells for a known pathogenic variant but no effect for the two germline variants detected in the study. We therefore propose that both germline variants are classified as likely benign. In this study, we show that RUNX1 germline variants are rare in Danish patients with MN and use a novel assay for functional classification of germline RUNX1 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitGerm-Line MutationMyeloproliferative DisordersLeukemia, Myeloid, AcuteHumansGenetic Predisposition to DiseaseMaleFemaleMiddle AgedAdultAgedAdolescent

Substanzen

Core Binding Factor Alpha 2 SubunitRUNX1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Biotech Research and Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Haematology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Haematology, Odense University Hospital, Odense, Denmark.
  • Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
  • Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Nikolaj Juul Nitschke, Marwa Almosailleakh, Yiyuan Niu, Jakob Werner Hansen, Klas Raaschou-Jensen, Jakob Schmidt Jespersen, Marianne Tang Severinsen, Anne Stidsholt Roug, Morten Frödin, Kirsten Grønbæk

Förderung

  • Horizon 2020 Framework Programme
  • Rigshospitalet’s Research Foundation
  • Danish Cancer Society
  • Greater Copenhagen Health Science Partners
  • Novo Nordisk Foundation

Zitieren

APA

Nitschke, N. J., Almosailleakh, M., Niu, Y., Hansen, J. W., Raaschou-Jensen, K., Jespersen, J. S., Severinsen, M. T., Roug, A. S., Frödin, M., Weischenfeldt, J. L., Andersen, M. K., & Grønbæk, K. (2023). Frequency and Functional Characterization of RUNX1 Germline Variants in Myeloid Neoplasms. Human Mutation, 2023, 1-11. https://doi.org/10.1155/2023/4738660

Vancouver

Nitschke NJ, Almosailleakh M, Niu Y, Hansen JW, Raaschou-Jensen K, Jespersen JS, et al. Frequency and Functional Characterization of RUNX1 Germline Variants in Myeloid Neoplasms. Human Mutation. 2023;2023:1-11. doi:10.1155/2023/4738660

BibTeX
@article{Nitschke2023,
  author = {Nitschke, Nikolaj Juul and Almosailleakh, Marwa and Niu, Yiyuan and Hansen, Jakob Werner and Raaschou-Jensen, Klas and Jespersen, Jakob Schmidt and Severinsen, Marianne Tang and Roug, Anne Stidsholt and Frödin, Morten and Weischenfeldt, Joachim Lütken and Andersen, Mette Klarskov and Grønbæk, Kirsten},
  title = {Frequency and Functional Characterization of RUNX1 Germline Variants in Myeloid Neoplasms},
  journal = {Human Mutation},
  year = {2023},
  volume = {2023},
  pages = {1--11},
  doi = {10.1155/2023/4738660}
}
Kostenlos starten →